文献速递呼吸衰竭与机械通气心脑血管急症

特发性肺动脉高压的表型分析:一项注册研究

Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis.
PubMed 文献 · Lancet Respir Med · 2022-06-28
一句话结论符合特发性肺动脉高压诊断标准、DLCO低于预测值45%且有吸烟史的患者,其临床特征与生存更接近肺疾病所致肺动脉高压,而非经典特发性肺动脉高压。

该研究分析COMPERA(2007年启动)和ASPIRE(2001年起)两个欧洲肺动脉高压注册库,比较经典特发性肺动脉高压、伴肺表型的特发性肺动脉高压(DLCO低于预测值45%且有吸烟史)及第3组肺动脉高压(肺疾病所致)患者的特征、治疗反应与生存。伴肺表型的特发性肺动脉高压患者年龄更大、女性比例更低,多数肺功能接近正常而DLCO严重降低,CT上肺实质受累多无或轻微。COMPERA中,该组WHO功能分级改善率26%、6分钟步行距离中位改善25 m、NT-proBNP中位降低27%,均低于经典特发性肺动脉高压(54%、63 m、58%),与第3组肺动脉高压相近。两个注册库中,伴肺表型的特发性肺动脉高压1年生存89%(COMPERA)和79%(ASPIRE)、5年生存31%和21%,均差于经典特发性肺动脉高压(1年95%和98%;5年84%和80%)。

要点

  • 伴肺表型的特发性肺动脉高压定义为DLCO低于预测值45%且有吸烟史,其1年生存89%(COMPERA)和79%(ASPIRE),差于经典特发性肺动脉高压的95%和98%。
  • 该组5年生存仅31%(COMPERA)和21%(ASPIRE),与第3组肺动脉高压(26%和18%)接近,远低于经典特发性肺动脉高压(84%和80%)。
  • COMPERA中该组首次随访WHO功能分级改善率26%,低于经典特发性肺动脉高压的54%(p<0·0001),与第3组肺动脉高压的22%无显著差异(p=0·194)。
  • 该组6分钟步行距离中位改善25 m、NT-proBNP中位降低27%,均低于经典特发性肺动脉高压(63 m,p=0·0015;58%,p=0·0043)。
  • 多数伴肺表型的特发性肺动脉高压患者肺功能接近正常、DLCO严重降低,CT上肺实质受累多无或轻微。

适用人群与场景

  • COMPERA和ASPIRE两个欧洲肺动脉高压注册库中诊断为特发性肺动脉高压的患者。
  • 伴肺表型:DLCO低于预测值45%且有吸烟史。
  • 经典特发性肺动脉高压:无心肺合并症且DLCO为预测值45%或以上。
  • 对照为第3组肺动脉高压(肺疾病所致肺动脉高压)。

诊断标准与关键阈值

  • 伴肺表型的特发性肺动脉高压:符合特发性肺动脉高压诊断标准,DLCO低于预测值45%,且有吸烟史。
  • 经典特发性肺动脉高压:无心肺合并症且DLCO为预测值45%或以上。

研究设计与关键结果

  • 研究类型为两个欧洲肺动脉高压注册库(COMPERA,2007年启动;ASPIRE,2001年起)的分析;纳入经典特发性肺动脉高压128例(COMPERA)和185例(ASPIRE)、伴肺表型的特发性肺动脉高压268例(COMPERA)和139例(ASPIRE)、第3组肺动脉高压910例(COMPERA)和375例(ASPIRE)。
  • 伴肺表型的特发性肺动脉高压中位年龄72岁(IQR 65-78,COMPERA)和71岁(65-76,ASPIRE),第3组肺动脉高压71岁(65-77)和69岁(63-74),均高于经典特发性肺动脉高压的45岁(32-60)和52岁(38-64)(两个注册库中伴肺表型 vs 经典特发性肺动脉高压均p<0·0001)。
  • 经典特发性肺动脉高压女性分别为99例(77%,COMPERA)和133例(72%,ASPIRE),伴肺表型女性为95例(35%,COMPERA)和75例(54%,ASPIRE),第3组肺动脉高压为336例(37%,COMPERA)和148例(39%,ASPIRE)。
  • COMPERA首次随访的治疗反应:WHO功能分级改善见于经典特发性肺动脉高压54%、伴肺表型26%、第3组肺动脉高压22%(经典 vs 伴肺表型p<0·0001;伴肺表型 vs 第3组p=0·194)。
  • 6分钟步行距离中位改善分别为63 m、25 m、23 m(经典 vs 伴肺表型p=0·0015;伴肺表型 vs 第3组p=0·64)。
  • NT-proBNP中位降低分别为58%、27%、16%(经典 vs 伴肺表型p=0·0043;伴肺表型 vs 第3组p=0·14)。
  • 生存:伴肺表型的特发性肺动脉高压1年89%(COMPERA)和79%(ASPIRE)、5年31%和21%;第3组肺动脉高压1年78%和64%、5年26%和18%;经典特发性肺动脉高压1年95%和98%、5年84%和80%(两个注册库中伴肺表型 vs 经典特发性肺动脉高压均p<0·0001)。

证据类型、等级与局限

  • 证据类型:基于COMPERA和ASPIRE两个欧洲肺动脉高压注册库的分析。
  • 局限:原文未报告局限性;作者在解释中指出这些观察对发病机制、诊断和治疗有意义,需要进一步探索。

对床旁实践的改变

  • 对于符合特发性肺动脉高压诊断标准但DLCO低于预测值45%且有吸烟史的患者,作者认为其表现更接近肺疾病所致肺动脉高压而非经典特发性肺动脉高压,对发病机制、诊断和治疗有意义,需要进一步探索。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Among patients meeting diagnostic criteria for idiopathic pulmonary arterial hypertension (IPAH), there is an emerging lung phenotype characterised by a low diffusion capacity for carbon monoxide (DLCO) and a smoking history. The present study aimed at a detailed characterisation of these patients.

METHODS: We analysed data from two European pulmonary hypertension registries, COMPERA (launched in 2007) and ASPIRE (from 2001 onwards), to identify patients diagnosed with IPAH and a lung phenotype defined by a DLCO of less than 45% predicted and a smoking history. We compared patient characteristics, response to therapy, and survival of these patients to patients with classical IPAH (defined by the absence of cardiopulmonary comorbidities and a DLCO of 45% or more predicted) and patients with pulmonary hypertension due to lung disease (group 3 pulmonary hypertension).

FINDINGS: The analysis included 128 (COMPERA) and 185 (ASPIRE) patients with classical IPAH, 268 (COMPERA) and 139 (ASPIRE) patients with IPAH and a lung phenotype, and 910 (COMPERA) and 375 (ASPIRE) patients with pulmonary hypertension due to lung disease. Most patients with IPAH and a lung phenotype had normal or near normal spirometry, a severe reduction in DLCO, with the majority having no or a mild degree of parenchymal lung involvement on chest computed tomography. Patients with IPAH and a lung phenotype (median age, 72 years [IQR 65-78] in COMPERA and 71 years [65-76] in ASPIRE) and patients with group 3 pulmonary hypertension (median age 71 years [65-77] in COMPERA and 69 years [63-74] in ASPIRE) were older than those with classical IPAH (median age, 45 years [32-60] in COMPERA and 52 years [38-64] in ASPIRE; p&lt;0·0001 for IPAH with a lung phenotype vs classical IPAH in both registries). While 99 (77%) patients in COMPERA and 133 (72%) patients in ASPIRE with classical IPAH were female, there was a lower proportion of female patients in the IPAH and a lung phenotype cohort (95 [35%] COMPERA; 75 [54%] ASPIRE), which was similar to group 3 pulmonary hypertension (336 [37%] COMPERA; 148 [39%] ASPIRE]). Response to pulmonary arterial hypertension therapies at first follow-up was available from COMPERA. Improvements in WHO functional class were observed in 54% of patients with classical IPAH, 26% of patients with IPAH with a lung phenotype, and 22% of patients with group 3 pulmonary hypertension (p&lt;0·0001 for classical IPAH vs IPAH and a lung phenotype, and p=0·194 for IPAH and a lung phenotype vs group 3 pulmonary hypertension); median improvements in 6 min walking distance were 63 m, 25 m, and 23 m for these cohorts respectively (p=0·0015 for classical IPAH vs IPAH and a lung phenotype, and p=0·64 for IPAH and a lung phenotype vs group 3 pulmonary hypertension), and median reductions in N-terminal-pro-brain-natriuretic-peptide were 58%, 27%, and 16% respectively (p=0·0043 for classical IPAH vs IPAH and a lung phenotype, and p=0·14 for IPAH and a lung phenotype vs group 3 pulmonary hypertension). In both registries, survival of patients with IPAH and a lung phenotype (1 year, 89% in COMPERA and 79% in ASPIRE; 5 years, 31% in COMPERA and 21% in ASPIRE) and group 3 pulmonary hypertension (1 year, 78% in COMPERA and 64% in ASPIRE; 5 years, 26% in COMPERA and 18% in ASPIRE) was worse than survival of patients with classical IPAH (1 year, 95% in COMPERA and 98% in ASPIRE; 5 years, 84% in COMPERA and 80% in ASPIRE; p&lt;0·0001 for IPAH with a lung phenotype vs classical IPAH in both registries).

INTERPRETATION: A cohort of patients meeting diagnostic criteria for IPAH with a distinct, presumably smoking-related form of pulmonary hypertension accompanied by a low DLCO, resemble patients with pulmonary hypertension due to lung disease rather than classical IPAH. These observations have pathogenetic, diagnostic, and therapeutic implications, which require further exploration.

FUNDING: COMPERA is funded by unrestricted grants from Acceleron, Bayer, GlaxoSmithKline, Janssen, and OMT. The ASPIRE Registry is supported by Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

参考来源

  1. Hoeper MM, Dwivedi K, Pausch C, et al. Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis. Lancet Respir Med. 2022. PMID: 35777416. doi:10.1016/S2213-2600(22)00097-2

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。